Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087900 | 0.87 | MAPT (0.33) | ALDH1A1 | |
| SCHEMBL4076103 | 0.82 | HSD11B1 (0.33) | ALOX5APFEN1SMN1; SMN2TNF | |
| SCHEMBL4085041 | 0.82 | ALOX5AP (0.31) | ALOX5APFEN1 | |
| SCHEMBL4079791 | 0.77 | MAPT (0.37) | SMN1; SMN2S1PR1ALDH1A1 | |
| SCHEMBL4079811 | 0.77 | ALDH1A1 (0.39) | SMN1; SMN2S1PR1ALDH1A1 | |
| SCHEMBL10993583 | 0.74 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL1203492 | 0.74 | ALDH1A1 (0.34) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL3655116 | 0.74 | ALDH1A1 (0.34) | ALOX5APFEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1204255 | 0.73 | POLB (0.36) | ALDH1A1 | |
| SCHEMBL1203818 | 0.72 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | ALOX5AP 2950/4885FEN1 1340/4885SMN1; SMN2 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.